Pharmacotherapy of onychomycosis

Bibliography

• BARAN R, HAY RJ, TOSTI A, HANEKE E: A new classification of onychomycosis. Br. J. Dermatol (1998) 119:567–571.
   Google Scholar
• ••A state of the art method of onychomycosisclassification.
   Google Scholar
• BARAN R: Diagnostic clinique des onychomycoses. In: Onychomycoses. Baran R, Pierard GE (Eds). Abreges Masson, Paris (2004), pp 37–90.
   Google Scholar
• ARRESE JE, PIERARD-FRANCHIMONT C, GREIMERS R, PIERARD GE: Fungi in onychomycosis. A study by immunohistochemistry and dual flow cytometry. j Eur. Acad. Dermatol VenereoL (1995) 4:123–130.
   Google Scholar
• PIERARD GE, ARRESE JE, DE DONCKER P, PIERARD-FRANCHIMONT C: Present and potential diagnostic techniques in onychomycosis. J. Am. Acad. Dermatol (1996) 34:273–277.
   PubMed Web of Science ®Google Scholar
• •New diagnostic methods for onychomycoses.
   Google Scholar
• PIERARD GE, ARRESE JE, QUATRESOOZ P: Histomycologie de la biodiversite des onychomycoses. In: Onychomycoses. Baran R, Pierard GE (Eds). Abreges Masson, Paris (2004), pp 91–104.
   Google Scholar
• EVANS EGV: Causative pathogens in onychomycosis and the possibility of treatment resistance. A review. J. Am. Acad. Dermatol (1998) 38:S32–S36.
   Web of Science ®Google Scholar
• ARRESE JE, PIERARD-FRANCHMONT C, PIERARD GE: Facing up to the diagnostic uncertainty and management of onychomycosis. Int. J. Dermatol (1999) 38:S1–S6.
   Web of Science ®Google Scholar
• ••A critical evaluation of diagnostic methodsand therapies of onychomycoses.
   Google Scholar
• CHABASSE D, BARAN R, FEUILHADE DE CHAUVIN MJ: Les onychomycoses. I- Epiderniologie, etiologie. Mycol. Med. (2000) 10:177–190.
   Google Scholar
• CHABASSE D: Epiderniologie et etiologie des onychomycoses. In: Onychomycoses. Baran R, Pierard GE (Eds). Abreges Masson, Paris (2004), pp 1–35.
   Google Scholar
• ARRESE JE, PIERARD-FRANCHIMONT C, PIERARD GE: A plea to bridge the gap between antifungals and onychomycosis management. Am. J. Clin. DermatoL (2001) 2:281–284.
   PubMedGoogle Scholar
• ARRESE JE, PIERARD GE: Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology (2003) 207:255–260.
   PubMed Web of Science ®Google Scholar
• ARRESE JE, DE DONCKER P, ODDS F, PIERARD GE: Reduction in the growth of non dermatophyte moulds by itraconazole: evaluation by corneofungimetry bioassay. Mycoses (1998) 41:461–465.
   PubMed Web of Science ®Google Scholar
• ••Bioassay predicting the in vivo antifungal activity against moulds.
   Google Scholar
• OSBORNE CS, LEITNER I, FAVRE B, RYDER NS: Antifungal drug response in an in vitro model of dermatophyte nail infection. Med. Mycol. (2004) 42:159–163.
   PubMed Web of Science ®Google Scholar
• FLAGOTHIER C, PIERARD-FRANCHIMONT C, PIERARD GE: New insights in the effect of amorolfine nail lacquer. Mycoses (2005) 48(2):91–94.
   PubMed Web of Science ®Google Scholar
• DE DONCKER P: Pharmacokinetics of orally administered antifitngals in onychomycosis. Int. j Dermatol. (1999) 38:S10–S27.
   Web of Science ®Google Scholar
• POLAK AM, DIXON DM: Antifungal activity of amorolfine in vitro and in vivo. In: Recent trends in the discovery, development and evaluation of antifitngal agents. Fromtling R (Ed.) JR Prous Science Publications, Barcelona, Spain (1987) 555–573.
   Google Scholar
• POLAK AM: Preclinical date and mode ofaction of amorolfine. Clin. Exp. Dermatol. (1992) 1:8–12.
   Google Scholar
• MENSING H, POLAK-WYSS A, SPLANEMANN V: Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychoycosis: comparison of two nail lacquer formulations. Clin. Exp. Dermatol. (1992) 17:S29–S32.
   Google Scholar
• POLAK A: Kinetics of amorolfine in human nails. Mycoses (1993)36:101–103.
   PubMed Web of Science ®Google Scholar
• LAUHARANTA J: Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin. Exp. Dermatol (1992) 1:41–43.
   Google Scholar
• REINEL D, CLARKE C: Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once weekly versus twice-weekly. Clin. Exp. Dermatol. (1992) 1:44–49.
   Google Scholar
• ZAUG M, BERGSTRASSER M: Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin. Exp. Dermatol. (1992) 18:61–70.
   Google Scholar
• MALESZKA R, RATAJCZAK V, TUREK-KRASINSKA K et al.: The use of amorolfine in the treatment of dermatophyte onychomycosis. Prz. Dermatol. (2002) 89:493.
   Google Scholar
• GUPTA AK: Ciclopirox: an overview. Int. J.Dermatol. (2001) 40:305–310.
   PubMed Web of Science ®Google Scholar
• BOHN M, KRAEMER K: The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J. Am. Pediatr. Med. Assoc. (2000) 90:491–494.
   PubMed Web of Science ®Google Scholar
• BOHN M, KRAEMER K: Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J. Am. Acad. Dermatol. (2000) 43: S57–S69.
   Web of Science ®Google Scholar
• MARKUS A: Hydroxy-pyridones: outstanding biological properties. In: Hydroxy-pyridones as antifungal agents with special emphasis on onychomycosis. Shuster (ed.) Springer, Berlin, Germany (1999).
   Google Scholar
• CESCHIN-ROQUES C, HANEL H, PRUJA-BOUGARET S, LUC J, VANDERMANDER J, MICHEL G: Ciclopirox nail lacquer 8%: in vivo penetration into and through nails and in vitro effect. Skin PharmacoL (1991) 4:89–94.
   PubMedGoogle Scholar
• BARAN R, HAY RJ, ECKART H, TOSTI A, PIRACCINI BM: Onychomycosis: The current approach to diagnosis and therapy. Martin Dunitz Ltd., London, UK (1999) p 44.
   Google Scholar
• SEEBACHER C: Action mechanisms ofmodern antifungal agents and resulting problems in the management of onychomycosis. Mycoses (2003) 46:506–510.
   PubMed Web of Science ®Google Scholar
• JOMARD P, LUC J, ROQUES C: Activité fongicide in vitro du ciclopirox. j MycoL Med. (2004) 14:78–82.
   Google Scholar
• GUPTA AK, JOSEPH WS: Ciclopirox 8%nail lacquer in the treatment of onychomycosis of the toenails in the United States. J. Am. Podriat. Med. Assoc. (2000) 90:495–501.
   PubMed Web of Science ®Google Scholar
• SEEBACHER C, NIETSCH KH, ULBRICHT HM: A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutts (2001) 68:17–22.
   PubMed Web of Science ®Google Scholar
• NOLTING S: Open studies of ciclopirox nail lacquer in onychomycosis. A review. In: Hydroxy-Pyridones as antifitngal agents with special emphasis on onychomycosis. Shuster S, Springer-Verlag, Berlin, Germany (1999) pp 75–80.
   Google Scholar
• GUPTA AK, FLECKMAN P, BARAN R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. (2000) 43:S70–S80.
   Web of Science ®Google Scholar
• PIERARD GE, RURANGIRWA A, PIERARD-FRANCHIMONT C: Bioavailability of fluconazole and ketoconazole in human stratum corneum and oral mucosa. Clin. Exp. Dermatol (1991) 16:168–171.
   PubMed Web of Science ®Google Scholar
• HUMPHREY MJ, JEVONS S, TARBIT MH: Pharmacokinetic evaluation of UK-49, 858, a metabolically stable triazole antifungal drug, in animals and man. Antimicrob. Agents Chemother. (1985) 28:648–653.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE D, RYCKELYNCK JP: Clinical pharmacokientics of fluconazole. Clin. Pharmacokinet. (1993) 24:10–27.
   PubMed Web of Science ®Google Scholar
• FAERGEMANN J, LAUFEN H: Levels of fluconazole in normal and diseased nails during and after treatment of oychomycosis in toenails with fluconazole 150 mg once weekly. Acta Derm. Venereol (1996) 76:219–221.
   PubMed Web of Science ®Google Scholar
• HAY RJ: Pharmacodynamic and pharmacokinetic evaluation of fluconazole in skin and nails. Int. J. Dermatol (1992) 31:S6–S7.
   Google Scholar
• WILDFEUER A, FAERGEMANN J, LAUFEN H et al.: Bioavailability of fluconazole in the skin after oral medication. Mycoses (1994) 37:127–130.
   PubMed Web of Science ®Google Scholar
• FRAKI J, HEIKKILA H, KERO M et al: An open-label, non-comparative study of the efficacy and safety of fluconazole in the treatment of onychomycosis. Current Ther. Res. (1997) 58:481–491.
   Google Scholar
• RICH P, SCHER RK, BRENEMAN D et al.: Pharmacokinetics of three doses (150, 300 and 450 mg) in distal subungual onychomycosis of the toenail./ Am. Acad. Dermatol. (1998) 38: S103–S109.
   Google Scholar
• SAWN RC, DRAKE L, BABLE D et al: Pharmacokinetics of three once weekly doses (150, 300 and 450 mg) in distal subungual onychomycosis of the fingernail. J. Am. Acad. Dermatol (1998) 38: S110–S116.
   Web of Science ®Google Scholar
• KATZ HI: Drug interactions of the newer oral antifungal agents. Br. J. Dermatol. (1999) 141:S26–S32.
   Web of Science ®Google Scholar
• GUPTA AK, KATZ HI, SHEAR NH: Drug interactions with itraconazole, fluconazole and terbinafine and their management. J. Am. Acad. Dermatol. (1999) 41:237–249.
   PubMed Web of Science ®Google Scholar
• SHEAR N, DRAKE L, GUPTA A et al.: The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology (2000) 201:196–203.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of drug interactions.
   Google Scholar
• SHAPIRO LE, SHEAR NH: Drug interactions: proteins, pumps, and P450s. J. Am. Acad. Dermatol (2002) 47:467–484.
   PubMed Web of Science ®Google Scholar
• KONNIKOV N, RAYNHAM H: Oral antifungal agents. In: Fitzpatrick's Dermatology in general medicine. 6th edn. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA. Katz SI (Eds) Mc Graw-Hill, New York, USA (2003) 2443–2448.
   Google Scholar
• PIERARD GE, ARRESE ESTRADA J, PIERARD-FRANCHIMONT C: Treatment of onychomycosis. Traditional approaches. J. Am. Acad. Dermatol (1993) 29:S41–S45.
   Google Scholar
• GUPTA AK, SCHER RK, DE DONCKER P: Current management of onychomycosis. DermatoL Clin. (1997) 15:121–135.
   PubMed Web of Science ®Google Scholar
• SCHAFER-KORTING M, KORTING HC, MUTSCHLER E: Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur. J. Clin. Pharmacol (1985) 29:109–113.
   PubMed Web of Science ®Google Scholar
• KORTING HC, SCHAFER-KORTING M, ZIENICKE H et al.: Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with itraconazole. Antimicrob. Ag. Chemoth. (1993) 37:2064–2068.
   PubMed Web of Science ®Google Scholar
• KABASAKALIAN P: Parameters affecting absorption of griseofulvin in a human subject using urinary metabolite excretion data./ Pharm. Sci. (1970) 59:595.
   PubMed Web of Science ®Google Scholar
• BATES TR, SEQUEIRA JAL: Use of 24 hr urinary excretion to assess the bioavailability of grisefulvin in humans. J. Pharm. Sci. (1975) 64:709.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM J: Oral, topical and parenteral antifungal treatment with itraconazole in normal and in immunocompromised animals. Mycoses (1989) 32:14–34.
   PubMed Web of Science ®Google Scholar
• CAUWENBERGH G, DEGREEF H, HEYKANTS J, WOESTENBORGHS R, VAN ROOY P, HAVERANS K: Pharmacokinetic profile of orally administered itraconazole in human skin. J. Am. Acad. Dermatol (1988) 18:263–268.
   PubMed Web of Science ®Google Scholar
• ••A milestone study on itraconazolepharmacokinetics in skin.
   Google Scholar
• GUPTA AK, SHEAR NH: The new oral antifungal agents for onychomycosis of the toenails. J. Eur. Acad. Dermatol. Vener. (1999) 13:1–13.
   PubMed Web of Science ®Google Scholar
• •A thorough, comparative review of oral treatments for onychomycosis.
   Google Scholar
• PIERARD GE, ARRESE JE, PIERARD-FRANCHIMONT C: Itraconazole. Expert Opin. Pharmacother. (2000) 1:287–304.
   PubMedGoogle Scholar
• ••A comprehensive review of itraconazoletherapy.
   Google Scholar
• PIERARD GE, ARRESE JE, PIERARD-FRANCHIMONT C: Itraconazole corneofungimetry bioassay on Ma/assezia species. Mycoses (2004) 47:418–421.
   PubMed Web of Science ®Google Scholar
• PIERARD GE, KHARFI M, SALOMON-NEIRA MD, KAMOUN MR, PIERARD-FRANCHIMONT C: Itraconazole in human aspergillosis revisited. J. MycoL Med. (2004) 14:192–200.
   Web of Science ®Google Scholar
• GROLL AH, PISCITELLI SC, WALSH TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. PharmacoL (1998) 44:343–500.
   PubMedGoogle Scholar
• VAN CUTSEM J, VAN GERVEN F, JANSSEN PAJ: Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev. Infect Dis. (1987) 9:S15–S32.
   Google Scholar
• PIERARD GE, ARRESE JE, DE DONCKER P: Antifitngal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J. Am. Acad. Dermatol (1995) 32:429–435.
   PubMed Web of Science ®Google Scholar
• ••Bioassay predicting the in vivo antifungalactivity against dermatophytes and yeasts.
   Google Scholar
• GUPTA AK, DE DONCKER P, SCHER RK et al.: Itraconazole for the treatment of onychomycosis. Int. J. DermatoL (1998) 37(4):303–308.
   PubMed Web of Science ®Google Scholar
• LEYDEN J: Pharmacokinetics and pharmacology of terbinafine and itraconazole. J. Am. Acad. Dermatol (1998) 38: S42–S47.
   Web of Science ®Google Scholar
• BARAN R, DE DONCKER P: Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm. Venereol. (1996) 76:82–83.
   PubMed Web of Science ®Google Scholar
• HAVU V BRANDT H, HEIKKILA H et al.: Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. Br. J. DermatoL (1999) 140:96–101.
   Google Scholar
• DE DONCKER PD, DECROIX J, PIERARD GE et al.: Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch. Dermatol (1996) 132:34–41.
   Google Scholar
• ••A milestone study on itraconazole pulsedosing regimen.
   Google Scholar
• HAVU V BRANDT H, HEIKKILA H et al.: A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br. J. Dermatol (1997) 136:230–234.
   Google Scholar
• INGBER A: Intermittent low dose itraconazole treatment for onychomycosis-long term follow-up. Med. MycoL (2001) 39:471–473.
   PubMed Web of Science ®Google Scholar
• BARONE JA, MOSKOVITCH BL, GUARNIERI J et al.: Enhanced bioavailability of itraconazole in hydroxypropyl-fl-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents. Chemother. (1998) 42:1862–1865.
   PubMed Web of Science ®Google Scholar
• VAN DE VELDE VJ, VAN PEER AP, HEYKANTS JJ et al.: Effects of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formlation of itraconazole. Pharmacother. (1996) 16:424–428.
   Google Scholar
• MENICHETTI F, DEL FAVERO A, MARTINO P et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin. Infect. Dis. (1998) 28:250–255.
   Web of Science ®Google Scholar
• ••The efficacy of itraconazole oral solutionin prophylaxis of mycoses.
   Google Scholar
• GLASMACHER A, HALN C, MOLITOR E, MARKLEIN G, SAUERBRUCH T, SCHMIDT-WOLF IG: Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regiments using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses (1999) 42:591–600.
   PubMed Web of Science ®Google Scholar
• STEVENS DA: Itraconazole in cyclodextrin solution. Pharmacother. (1999) 19:603–611.
   PubMed Web of Science ®Google Scholar
• WARNOCK DW, TURNER A, BURKE J: Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. Antimicrob. Chemother. (1988) 21:93–100.
   Google Scholar
• GUPTA AK, DE DONCKER P, HANEKE E: Itraconazole pulse therapy for the treatment of Candida onychomycosis. J. Eur. Acad. Dermatol. VenereoL (2000) 15 (2):112–1 1 5.
   Google Scholar
• DE DONCKER P, SCHER R, BARAN R et al.: Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J. Am. Acad. Dermatol. (1997) 36:173–177.
   PubMed Web of Science ®Google Scholar
• ••A unique multi-centre study on thetherapy of mould onychomycoses.
   Google Scholar
• ODOM RB, ALI R, SCHER RK et a/... A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychopycosis of the fingernail./ Am. Dermatol. (1997) 36:231–235.
   Google Scholar
• HANEKE E, ABECK D, RING J: Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail-onychomycosis : a multicentre trial. Mycoses (1998) 41:521–527.
   PubMed Web of Science ®Google Scholar
• DE DONCKER P, GUPTA AK, MARYNISSEN G et al.: Itraconazole pulse therapy for onychomycosis and dermatomycoses : an overview. J. Am. Acad. Dermatol. (1998) 37:969–974.
   Web of Science ®Google Scholar
• WANG DL, WANG AP, LI RY, WANG R: Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. Dermatology (1999) 199:47–49.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, MADDIN S, ARLETTE J et al.: Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. J. Dermatol. Treat. (2000) 11:33–37.
   Web of Science ®Google Scholar
• PIERARD-FRANCHIMONT C, DE DONCKER P, VAN DE VELDE JACQUMIN P, ARRESE JE, PIERARD GE: Paradoxical response to itraconazole treatment in a patient with onychomycosis caused by Microsporum gypseum. Ann. Soc. Beige Med. Trop. (1995) 75:211–217.
   PubMedGoogle Scholar
• GROLL AH, PISCITELLI SC, WALSH TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. PharmacoL (1998) 44:343–500.
   PubMedGoogle Scholar
• VENKATAKRISHNAN K, VON MOLTKE LL, GREENBLATT DJ: Effects of the antifungal agents on oxidative drug metabolism : clinical relevance. Clin. Pharmacoki net. (2000) 38:111–180.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, CHWETZOFF E, DEL ROSSO J, BARAN R: Hepatic safety of itraconazole. J. Cutan. Med. Surg. (2002) 6:210–213.
   PubMed Web of Science ®Google Scholar
• AHMAD SR, SINGER SJ, LEISSA BG: Congestive heart failure associated with itraconazole. Lancet (2001) 357:1716–1717.
   Web of Science ®Google Scholar
• ARRESE JE, FOGOUANG L, PIERARD-FRANCHIMONT C, PIERARD GE: Euclidean and fractal computer-assisted corneofungimetry. A comparison of 2% ketoconazole and 1% terbinafine topical formulations. Dermatology (2002) 204:222–227.
   Google Scholar
• GUPTA AK, RYDER JE: The use of oral antifungal agents to treat onychomycosis. DermatoL Clin. (2003) 21:469–479.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, KOHLI Y, BATRA R: In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med. MycoL (2005) 43:179–187.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, LEONARDI C, STOLTZ RRet aL: A Phase I/II randomized, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol. In press.
   Google Scholar
• ODDS F, VAN GERVEN F, WOESTENBORGHS F et aL: Activity in vitro and in vivo of a novel azole antifungal agent: R126638. Anti microb. Agents Chemother. (2004) 48:388–391.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, AUSMA J, BOHETS H et al.: The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp and Microsporum canis. Anti microb. Agents Chemother. (2004) 48:3272–3278.
   PubMed Web of Science ®Google Scholar
• PIERARD-FRANCHIMONT C, AUSMA J, WOUTERS Let aL :Activity of the triazole antifungal R126638 as assessed by corneofitngimetry. Skin PharmacoL PhysioL In press.
   Google Scholar
• PIERARD GE, HENRY F, AUSMA J et al.:A proof-to-concept study on seborrheic dermatitis using R126638 as a potent oral anti-Malassezia agent. Skin PharmacoL PhysioL In press.
   Google Scholar
• JENSSEN JC: Pharmacokinetics of terbinafine in humans. J. Dermatol. Treat. (1990) 1:S15–S18.
   Google Scholar
• KOVARIK JM, KIRKESSELI S, HUMBERT H, GRASS P, KUTZ K: Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br. J. Dermatol. (1992) 126:S8–S13.
   Web of Science ®Google Scholar
• FAERGEMANN J, ZEHENDER H, MILLERIOUX L: Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), hair and nails during and after 250 mg terbinafine orally once per day for 7 and 14 days. Clin. Exp. Dermatol. (1994) 19:121–126.
   PubMed Web of Science ®Google Scholar
• SCHATZ F, BRAUTIGAM M, BOBROWOLSKI E et aL: Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin. Exp. Dermatol. (1995) 20:377–383.
   PubMed Web of Science ®Google Scholar
• FINLAY AY, LEVER LR, THOMAS R, DYKES PJ: Nail matrix kinetics of oral terbinafine in onychoycosis and normal nails. J. Dermatol. Treat. (1990) 1:S51–S54.
   Google Scholar
• FINLAY AY: Pharmacokinetics of terbinafine in the nail. Br. J. Dermatol. (1992) 126:S28–S32.
   Web of Science ®Google Scholar
• EVANS G, SIGURGEIRSSON B: Double blind, randomized study of continous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Br. Med. J. (1999) 318:1031–1035.
   PubMed Web of Science ®Google Scholar
• CRIBIER BJ, PAUL C: Long-term efficacy of antifungals in toenail onychomycosis: a critical review. Br. J. Dermatol. (2001) 145:446–452.
   PubMed Web of Science ®Google Scholar
• CRAWFORD F, YOUNG P, GODFREY C et al.: Oral treatments for toenail onychomycosis: a systematic review. Arch. Dermatol. (2002) 138:811–816.
   PubMed Web of Science ®Google Scholar
• HAUGH M, HELOU S, BOISSEL JP, CRIBIER BJ: Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br. J. Dermatol. (2002) 147:118–21.
   PubMed Web of Science ®Google Scholar
• ••A meta-analysis on terbinafine treatment.
   Google Scholar
• SIGURGEIRSSON B, OLAFSSON JH, STEINSSON JB et al.: Long-term effectiveness of treatment with terbinafine versus itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch. Dermatol. (2002) 138:353–357.
   PubMed Web of Science ®Google Scholar
• TOSTI A. PIRACCINI BM, STING HI et al.: Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J. Am. Acad. Dermatol (1996) 34(4):595–600.
   Google Scholar
• GOODFIELD MJD, ANDREW L, EVANS EGV: Short term treatment of dermatophyte onychomycosis with terbinafine. Br. Med. J. (1992) 304:1151–1154.
   PubMedGoogle Scholar
• LEBWOHL MG, DANIEL CR, LEYDEN J et al.: Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte toenail onychomycosis. Int. J. Dermatol. (2001) 40:358–360.
   PubMed Web of Science ®Google Scholar
• SVEJGAARD EL, BRANDRUP F, KRAGBALLE K et al.: Oral terbinafine in toenail dermatophytosis. Acta Derm. VenereoL (1997) 77:66–69.
   PubMed Web of Science ®Google Scholar
• HEIKKILA H, STUBB S: Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br. J. Dermatol. (2002) 146:250–253.
   PubMed Web of Science ®Google Scholar
• BAUDRAZ-ROSSELET F, RAKOSI T, WILI PB, KENZELMAN R: Treatment of onychomycosis with terbinafine. Br. J. Dermatol. (1992) 126:S40–S46.
   Web of Science ®Google Scholar
• FINLAY AY, THOMAS R, DYKES PJ et al.: Descriptive correlations between various doses of oral terbinafine and concentrations in nail. J. Dermatol. Treat. (1994) 5:193–197.
   Google Scholar
• ALPSOY E, YILMAZ E, BASALAN E: Intermittent therapy with terbinafine for dermatophyte toe onychomycosis: a new approach. J. Dermatol (1996) 23:259–262.
   PubMedGoogle Scholar
• ZAIAS N, REBELL G. The successful treatment of Trichophyton rubrum nail bed (distal subungal) onychomycosis with intermittent pulse-dosed terbinafine. Arch. Dermatol. (2004):140:691–695.
   PubMed Web of Science ®Google Scholar
• FAERGEMANN J, ZEHENDER H, BOUKHABZA A et al.: A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication. Acta Derm. Venereol. (1997) 77(1):74–76.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, DEL ROSSO JQ: An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int. J. Dermatol. (2000) 39:401–411.
   PubMed Web of Science ®Google Scholar
• ••A review of a new therapeutic strategy.
   Google Scholar
• WATSON A, MARLEY J, ELLIS D, WILLIAMS T: Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J. Am. Acad. Dermatol. (1995) 33:775–779.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, BARAN R, SUMMERBELL R: Onychomycosis: strategies to improve efficacy and reduce recurrence. J. Eur. Acad. Dermatol. Venereol (2002) 16:579–586.
   PubMed Web of Science ®Google Scholar
• MEDOFF G, KOBAYASHI GS, KWANG CN et al.: Potentialisation of rifampicin and flucocytosine as antifungal antibiotics by amphotericin B. Proc. Soc. Exp. Biol. Med. (1971) 138:571–574.
   PubMed Web of Science ®Google Scholar
• POLACK A: The past, present and future of antimycotic combination therapy. Mycoses (1999) 42:355–370.
   PubMed Web of Science ®Google Scholar
• RUBIN MA, CARROLL KC, CAHILL BC: Caspofitngin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin. Infra-Dis. (2002) 34:1160–1161.
   PubMed Web of Science ®Google Scholar
• STEINBACH WJ, STEVENS DA, DENNING DW: Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. (2003) 37:S188–S224.
   PubMed Web of Science ®Google Scholar
• KONTOYIANNIS DP, HACHEM R, LEWIS RE et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer (2003) 98:292–299.
   PubMed Web of Science ®Google Scholar
• SUGAR AM: Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob. Agents Chemother. (1995) 39:1907–1912.
   PubMed Web of Science ®Google Scholar
• BOHME A, JUST-NUBLING G, BERGMANN L, SHAH PM, STILLE W, HOELZER D: Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J. Antimicrob. Chemother. (1999) 42:443–451.
   Google Scholar
• GLASMACHER A, HAHN C, LEUTNER C et al.: Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses (1999) 42:443–451.
   PubMed Web of Science ®Google Scholar
• REPKA MA, MIDIDODDI PK, STODGHILL ST: Influence of human nail etching for the assessment of topical onychomycosis therapies. Int. J. Pharmacol (2004) 282:95–106.
   Google Scholar
• REPKA MA, MIDIDODDI PK, STODGHILL SP: Influence of human nail etching for the assessment of topical onychomycosis therapies. Int. j Pharm. (2004) 282:95–106.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, KONNIKOV N, LYNDE CW: Sequential pulse therapy with itraconazole and terbinafine to treat onychomycosis of the fingernails. Dermatol. Treat. (2000) 11:151–154.
   Web of Science ®Google Scholar
• GUPTA A. LYNDE CW, KONNIKOV N: Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. (2001) 44:485–491.
   PubMed Web of Science ®Google Scholar
• PIERARD GE, PIERARD-FRANCHIMONT C, ARRESE JE: The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology (2000) 200:185–187.
   PubMed Web of Science ®Google Scholar
• •A new concept in oncyhomycosis treatment.
   Google Scholar
• GOFFIN V ARRESE J, PIERARD GE: Onychomycoses recalcitrantes et le low-cost BOAT' au fluconazole. Skin (2002) 5:145–147.
   Google Scholar
• PIERARD GE, PIERARD-FRANCHIMONT C, ARRESE JE: The boosted antifungal topical treatment (BATT) for onychomycosis. Med. Mycol. (2000) 38:391–392.
   PubMed Web of Science ®Google Scholar
• HAY RJ: A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofitlyin in patients with onychomycosis. Clin. Exp. Dermatol (1987) 12:175.
   PubMed Web of Science ®Google Scholar
• GUPTA AK and the ONYCHOMYCOSIS COMBINATION THERAPY STUDY GROUP: Randomized evaluation, blind, multicentre, Phase IV study of the efficacy and safety of ciclopirox nail laquer topical solution 8% in combination with oral terbinafine in the treatment of moderate to severe toenail onychomycosis. An analysis of dermatophyte positive patients. J. Drugs Dermatol. In press.
   Google Scholar
• KIM HC, JUNG KB, SHIN DH, KIM KH: Comparison of compliance and cure rate of systemic antifungal therapy versus combination therapy with systemic and topical agent in toenail onychomycosis. Kor. J. Med. MycoL (2002) 7:35–41.
   Google Scholar
• LAUHARANTA J, ZAUG M, POLAK A et al.: Combination of amorolfine with griseofitlyin: in vitro activity and clinical results in onychomycosis. J. Am. Med. Assoc. SEA (1993) 9\(Suppl. 4):23.
   Google Scholar
• ZAUG M: Amorolfine nail lacquer: clinical experience in onychomycosis. j Eur. Acad. DermatoL VenereoL (1995) 4:S23–S30.
   Google Scholar
• BARAN R, FEUILHADE M, DATRY A et al.: A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycosis affecting the nail region. Br. J. DermatoL (2000) 142:1177.
   PubMed Web of Science ®Google Scholar
• BARAN E, BOCHENSKI J, DUCZKOWSKI M, BARAN W: Combination therapy for onychomycosis with amorolfine nail lacquer and oral antifungal agents. MikoL Lek. (2003) 10:79–83.
   Google Scholar
• LECHA M, ALSINA M, TORRES M et al.: Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomised trial in Spain. Br. J. DermatoL (2001) 145\(Suppl. 60):21.
   Google Scholar
• RIGOPOULOS D, KATOULIS A, IOANNIDES D et al.: A randomised trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br. J. DermatoL (2003) 149:151.
   PubMed Web of Science ®Google Scholar
• SERGEEV Y, SERGEEV A: Pulsed combination therapy: the new option for onychomycosis. Mycoses (2001) 44\(Suppl. 1):68.
   Google Scholar
• HARMAN S, ASHBEE HR, EVANS EG: Testing of antifungal combinations against yeasts and dermatophytes. j DermatoL Treat. (2004) 15:104–107.
   PubMedGoogle Scholar
• EPSTEIN E: How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch. DermatoL (1998) 134:1551–1554.
   PubMedGoogle Scholar
• GOODFIELD MJD, EVANS EGV: Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection. J. DermatoL Treat. (2000) 11:259–262.
   Web of Science ®Google Scholar
• BARAN R, HAY RJ: Partial surgical avulsion of the nail in onychomycosis. Clin. Exp. DermatoL (1985) 23:305–313.
   Google Scholar
• BARAN R: Nail fungal infection and treatment. Hand Clin. (2002) 18:625–628.
   PubMed Web of Science ®Google Scholar